Answer
Fedratinib (Inrebic) inhibits wild-type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3), with higher inhibitory activity for JAK2 than for JAK1, JAK3 and TYK2.
Sources for this answer
- Inrebic 100 mg hard capsulesBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 9Document updated
Sources checked